ArticleFrontiers in endocrinology2026
Associations of C-reactive protein, triglyceride-glucose index, and the C-reactive protein-triglyceride glucose index with multistate trajectories in the cardiovascular-renal-diabetes cluster.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the associations of C-reactive protein (CRP), triglyceride-glucose (TyG) index, and their composite-the CRP-TyG index (CTI)-with sequential trajectories within the cardiovascular-renal-diabetes (CRD) cluster, including incident coronary artery disease (CAD), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), and multimorbidity. Methods: We analyzed 333,698 participants from the UK Biobank who were free of CAD, T2DM, and CKD at baseline. CRP and TyG were assessed individually and jointly through the CTI. Multistate Cox models were applied to evaluate six predefined transitions within the CRD cluster, with multimorbidity defined as the coexistence of at least two of CAD, T2DM, and CKD. Potential nonlinearity was assessed using restricted cubic splines, and time-dependent effects were examined with piecewise analyses. Joint exposure analyses assessed synergistic effects of CRP and TyG, while receiver operating characteristic (ROC) curves compared the predictive performance of CRP, TyG, their combination, and CTI. Subgroup and sensitivity analyses were performed to test heterogeneity and robustness. Results: During a median follow-up of 15.31 years (IQR, 14.54-16.03 years), CTI was consistently associated with higher risks of CAD (HR per 1-SD: 1.23, 95% CI: 1.21-1.25), T2DM (1.88, 95% CI: 1.84-1.92), CKD (1.22, 95% CI: 1.19-1.25), and multimorbidity (1.59, 95% CI: 1.55-1.64), outperforming CRP and TyG individually. CTI exhibited trajectory-specific heterogeneity, with nonlinear associations observed in most baseline-to-disease transitions (P for nonlinearity <0.05) and predominantly linear associations during progression from single diseases to multimorbidity (all P for nonlinearity >0.05). Moreover, higher CTI was associated with a time-dependent cumulative increase in multimorbidity risk. In joint exposure analyses, participants with both high CRP and high TyG had the greatest risks across outcomes, including CAD (HR 1.48, 95% CI: 1.40-1.56), CKD (HR 1.52, 95% CI: 1.40-1.64), T2DM (HR 3.63, 95% CI: 3.35-3.93), and multimorbidity (HR 2.64, 95% CI: 2.47-2.82). Conclusions: CRP, TyG, and CTI were strongly associated with both the onset and progression of the cardiovascular-renal-diabetes cluster. By integrating metabolic and inflammatory risk signals, CTI outperformed its individual components, underscoring its clinical utility for refined risk stratification and for guiding early, stage-specific prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.